Fidelity Investments
ARTV

Fidelity Investments’s Artiva Biotherapeutics ARTV Stock Holding History

Fidelity Investments’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.5K Buy
3,558
+29
+0.8% +$264 ﹤0.01% 4461
2026
Q1 		$22.7K Sell
3,529
-29
-0.8% -$143 ﹤0.01% 4460
2025
Q4 		$15.3K Sell
3,558
-1,362
-28% -$5.14K ﹤0.01% 4579
2025
Q3 		$14.1K Sell
4,920
-37,357
-88% -$100K ﹤0.01% 4499
2025
Q2 		$63.8K Buy
42,277
+38,722
+1,089% +$81.3K ﹤0.01% 3784
2025
Q1 		$10.7K Buy
3,555
+2,655
+295% +$14.3K ﹤0.01% 4475
2024
Q4 		$9.07K Buy
900
+740
+463% +$8.89K ﹤0.01% 4493
2024
Q3 		$2.47K Buy
+160
New +$1.85K ﹤0.01% 4762

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Fidelity Investments's ARTV Position: Q2 2026 in Review

Fidelity Investments increased its Artiva Biotherapeutics (ARTV) stake by 0.82% in Q2 2026, buying an estimated $264 and bringing the position to 3,558 shares worth $34.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4461.

Fidelity Investments first reported a position in ARTV in Q3 2024 and has held it in 8 quarters since. The position peaked at $63.8K in Q2 2025. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • Fidelity Investments held 3,558 shares of Artiva Biotherapeutics worth $34.5K as of Q2 2026.
  • Fidelity Investments bought 29 Artiva Biotherapeutics shares in Q2 2026, an estimated $264.
  • Artiva Biotherapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #4461 holding.
  • Fidelity Investments first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 8 quarters since.
  • Fidelity Investments's Artiva Biotherapeutics position peaked at $63.8K in Q2 2025.
  • 72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.